Skip to main content
News
Events
Contact us
Close Search
search
Menu
About us
About us
Team
Work with us
Our offering
Our offering
FAQs
Portfolio
Success stories
Partners
Apply
Apply
FAQs
search
News
Filter
All
All
Company interviews
Featured
Features
Interviews
Portfolio news
Team interviews
Uncategorized
Looking for an experienced drug developer to join an emerging biotech as COO
MT-act joins BaseLaunch portfolio
We welcome Hoffmann & Partner as our new domain partner
BaseLaunch summer get-together 2024
NXI Therapeutics extends pre-seed funding to CHF 3.5 million ahead of major seed round
9 tips for scientists who want to become entrepreneurs
Nature publication demonstrating Cimeio`s transformative approach towards blood cancers
AbbVie becomes a BaseLaunch partner
Alentis appoints Alberto Toso Chief Scientific Officer
Our partnership with CSL
We welcome VISCHER as our new domain partner
Podcast: How to build a compelling pitch deck for early stage ventures
KPMG renews partnership with BaseLaunch
FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund
Synendos Therapeutics granted EMA clinical trial authorisation
William Pao joins Alentis Therapeutics as independent board member
Novo Nordisk becomes a BaseLaunch partner
Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM
Ferring and PharmaBiome enter a collaboration and exclusive licensing agreement
TOLREMO treats first patient in phase I trial with TT125-802, a novel therapeutic agent to overcome transcriptional cancer drug resistance
T3 Pharma acquired by Boehringer Ingelheim for up to 450M Swiss francs
FDA clears Versameb’s VMB-100 for stress urinary incontinence treatment
Alentis Therapeutics doses first patient in phase 1/2 clinical trial of ALE.C04
FimmCyte announces the appointment of Dr. Markus Kalousek as chairperson
Onena Medicines secures 3.7 M Swiss francs investment
Johnson & Johnson Innovation renews its commitment
Cimeio collaborating with the University of Pennsylvania
Insights into Roche’s partnering and venture fund strategies
Salvina Therapeutics joins BaseLaunch portfolio
TOLREMO therapeutics secures USD 39 million
Do you have a question? Get in touch
info@baselaunch.ch
Contact us
Close Menu
About us
About us
Team
Work with us
Our offering
Our offering
FAQs
Portfolio
Success stories
Partners
Apply
Apply
FAQs
News
Events
Contact us